Wegovy Just Got Stronger: What the EU Approval of the 7.2 mg Dose Means for Patients in Ireland (2026)

All medical information is reviewed by our clinical partners at MedicOnline.

Dr. Jahan Khan, CMO @ MedicOnline

IMC 409788

For years, the question with Wegovy was simple: does it work? The answer was yes. The new question is more interesting: can it work even better? With the EU approval of a 7.2 mg dose in February 2026, the answer to that is also yes - and Ireland is next in line.

On 17 February 2026, the European Commission formally approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide) for adults with obesity across all 27 EU member states. The decision followed a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP), issued on 12 December 2025.

This is not a new drug. It is a higher-strength extension of the semaglutide already available in Ireland - and the clinical data behind it is compelling. At Bua Health, we want to make sure our patients understand exactly what this approval means, who it is relevant for, and what the realistic timeline to access looks like in Ireland.

What the STEP UP Trial Actually Showed

The approval is built on two Phase 3b trials published simultaneously in The Lancet Diabetes and Endocrinology in November 2025: STEP UP (adults with obesity without diabetes) and STEP UP T2D (adults with obesity and type 2 diabetes). The primary trial, STEP UP (Wharton et al., Lancet Diabetes Endocrinol. 2025;13(11):949-963) (full publication), enrolled 1,407 adults across 95 clinical sites in 11 countries over 72 weeks.

The headline results were significant. Among participants who adhered fully to treatment, those on semaglutide 7.2 mg lost an average of 20.7% of their body weight compared to 17.5% on the standard 2.4 mg dose and 2.4% on placebo. Under the treatment policy estimand, the figures were 18.7% versus 15.6% versus 3.9%.

• 20.7% mean weight loss with 7.2 mg (full adherence, 72 weeks)
• 33.2% of patients achieved 25% or greater body weight loss on 7.2 mg (vs 16.7% at 2.4 mg)
• Approximately 84% of weight lost came from fat mass - with muscle function preserved

That last figure deserves particular attention. The STEP UP data showed that approximately 84% of weight lost at 7.2 mg came from fat mass, with muscle function preserved - supporting the favourable benefit-risk profile the researchers concluded. The threshold of 25% weight loss is clinically meaningful because it approaches outcomes previously only associated with bariatric surgery and Mounjaro 15 mg.

Closing the Gap with Mounjaro

The competitive context matters also. The SURMOUNT-5 trial (Aronne et al., NEJM, 2025) (full publication) - the first direct head-to-head comparison of semaglutide and tirzepatide - showed Mounjaro 15 mg producing 20.2% mean weight loss versus 13.7% for Wegovy 2.4 mg. That gap gave tirzepatide a clear efficacy advantage at standard doses.

Wegovy 7.2 mg changes that picture substantially. At 20.7% mean weight loss with full adherence, the 7.2 mg dose delivers results now directly comparable to Mounjaro 15 mg - though these comparisons come from separate trials with different populations rather than a direct head-to-head, so they should be treated as indicative rather than definitive. Patients who need maximum weight loss now have a viable step-up option within the semaglutide class. If you're comparing both options in Ireland, see Wegovy vs Mounjaro in Ireland.

How the 7.2 mg Dose Is Administered - For Now

A dedicated single-dose 7.2 mg pen is not yet approved in the EU - Novo Nordisk has submitted an application for one and it may become available later in 2026. In the interim, the 7.2 mg dose is administered as three separate 2.4 mg injections in a single weekly sitting - maintaining the once-weekly schedule but requiring three consecutive injections rather than one.

Eligible patients can escalate directly from the 2.4 mg maintenance dose to 7.2 mg after a minimum of four weeks at the 2.4 mg level, where greater weight loss is clinically indicated. This is not a starting dose and is not appropriate for patients who have not already tolerated the 2.4 mg dose.

The 7.2 mg dose is a step-up option for specific patients - not a replacement for the 2.4 mg dose, which remains the standard maintenance dose for most people. The decision to escalate is a clinical one that should always be made with your doctor.

The Ireland Timeline: Where Things Stand

The critical point for Irish patients: the EU licence is confirmed. Practical access is a matter of supply and HPRA listing rather than a further regulatory hurdle.

Who Is the 7.2 mg Dose Actually For?

The 7.2 mg dose is designed for patients who have reached and tolerated the 2.4 mg maintenance dose but have not achieved their treatment goals - either because weight loss has plateaued or because their clinical objectives require greater reduction than 2.4 mg is delivering. For patients who are responding well to 2.4 mg, there is no clinical reason to escalate.

This is also particularly relevant for patients who previously felt they had to choose between semaglutide and tirzepatide purely on the basis of maximum efficacy. With 7.2 mg now matching Mounjaro 15 mg in weight loss outcomes, the choice becomes more nuanced - and the proven cardiovascular benefits of semaglutide (from the SELECT trial, NEJM 2023; full publication) become a more relevant differentiating factor for patients with heart disease.

Looking to get started or switch provider?

Finding the right path for your health is a significant decision, but you don't have to navigate it alone. At Bua Health, the process is simple, secure, and strictly doctor-led:

Our clinical partners at MedicOnline are ready to review your history and help you build a holistic plan that works for your life, not just your weight.

You can check your eligibility online at buahealth.ie in minutes.

Sources and References

• 1. Novo Nordisk / BioPharm International (February 2026). European Commission approves 7.2 mg once-weekly Wegovy dose. biopharminternational.com
• 2. Wharton S, et al; STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13(11):949-963. STEP UP study publication
• 3. Aronne LJ, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. SURMOUNT-5 study publication
• 4. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. SELECT study publication
• 5. European Medicines Agency. Wegovy (semaglutide) EPAR. ema.europa.eu/en/medicines/human/EPAR/wegovy

Related Blogs

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read